After Turmoil: Ex-Trump FDA Chief's Rocky Exit Leaves Billions in

POLICY WIRE — Washington, D.C. — For just over a year, the Food and Drug Administration (FDA) has functioned less like a sober scientific body and more like a perpetually swirling vortex. Its largest division, the drug center, cycled through six directors in that short span—a revolving door dizzying enough to make seasoned D.C. operatives wince. But now, the man at the epicenter of this bureaucratic maelstrom, Dr. Marty Makary, has quietly packed his bags, leaving behind an agency in disarray and a host of industry players, anti-abortion activists, and even vaping lobbyists nursing grievances.

It’s not every day a top federal official manages to alienate so many constituencies simultaneously. Makary, a surgeon and health researcher, rode into the FDA on a wave of Trump-era populism, largely fueled by his cable news appearances lambasting COVID-19 health measures. Yet, his tenure proves a rather blunt object in the nuanced art of Washington administration, characterized by internal strife, high-profile exits, and decisions often appearing more attuned to political currents than scientific principles. But he couldn’t keep everyone happy, could he?

Sources familiar with the matter—and frankly, the sheer volume of leaks spoke for itself—describe an environment where career staff morale bottomed out, scientific integrity appeared compromised, and experienced hands were systematically sidelined. Indeed, virtually all of the FDA’s senior career officials either left or were pushed out during his watch. The agency, which regulates everything from aspirin to cutting-edge biologics, oversees a staggering portion of the nation’s economy. Analysts estimate the agency’s purview impacts goods and services valued at upwards of trillions of dollars annually. The stakes here, for public health — and commerce, couldn’t be higher.

The outgoing chief’s particular flavor of chaos manifested most acutely in two areas: vaccine policy and product approvals for politically connected industries. Makary’s handpicked deputy, Dr. Vinay Prasad, famously suggested, without providing peer-reviewed data, that COVID shots were linked to pediatric deaths. His pronouncements led to internal memos outlining a drastic overhaul of vaccine protocols—a move that spurred a scathing denunciation from a dozen former FDA commissioners, warning it would “undermine the public interest” and “decimate vaccine development.” That’s pretty strong language from the folks who usually measure their words with calipers.

Then there’s the tightrope Makary attempted to walk with industry. On one side, he publicly championed “faster drug reviews,” even proposing radical measures like dropping certain study requirements and leveraging AI for evaluations. “We were trying to cut through decades of accumulated bureaucratic red tape,” Makary once told a right-wing radio show, framing his efforts as a battle against the deep state. And for a moment, it seemed to resonate. But industry, for all its clamoring for speed, also craves predictability, something in short supply under Makary.

Drugmakers found themselves in a bizarre limbo. Firms developing specialty therapies—often for rare or debilitating diseases—saw prior “go-aheads” suddenly reversed, replaced by demands for more studies. And this often occurred right after Prasad, his deputy, took charge of a specific review. On the other end of the spectrum, vaping executives, having initially fumed over stalled product approvals, eventually saw a sudden reversal in FDA policy last week. The agency loosened marketing guidelines — and authorized some of the first fruit-flavored e-cigarettes. But it was apparently too little, too late, for Makary.

Anti-abortion groups also piled on. They’d been leaning hard on the administration, alleging Makary was “slow-walking” an internal review of mifepristone, the abortion pill – a medication that’s been on the market for twenty-five years but remains a conservative lightning rod. And here’s where the politicking truly began to boil over.

“Dr. Makary has a proven track record, but the FDA simply can’t afford distractions right now,” Health Secretary Robert F. Kennedy Jr. told Policy Wire in an exclusive comment. “We need focused, efficient leadership, especially given the global health challenges and the demands placed on our pharmaceutical industries by the American public and international partners.”

Former President Trump himself offered a rather anodyne send-off: “He’s a great doctor, and he was having some difficulty. But he’s going to go on — and he’s going to do well.” Translation: it wasn’t working. The departure hands the reins, at least temporarily, to Kyle Diamantas, the agency’s chief for foods and an attorney with known ties to Donald Trump Jr. Expect a scramble for stability, then.

What This Means

Makary’s exit signals the inevitable fallout when an agency built on scientific rigor is perceived to bend to political winds. For Trump, it’s another mid-election-cycle leadership change that does little to quell accusations of White House instability. The administration, trying to project competence ahead of November, has yet another senior position to fill, and this one’s high-profile, drawing scrutiny from across the spectrum of lobbyists and public health advocates.

Economically, the unpredictability generated by Makary’s rapid policy shifts and staffing purges could deter investment in pharmaceutical innovation. Drugmakers thrive on clear, consistent regulatory pathways. The current turmoil likely translates into delayed product launches and increased costs, ultimately affecting consumer access and prices. And internationally, this regulatory volatility has real-world consequences. Nations across South Asia and the Muslim world, like Pakistan, frequently look to FDA approvals as a critical benchmark for their own drug procurement and regulatory frameworks. Makary’s “national interests” initiatives could have prioritized domestic pharmaceutical agendas over broader global health equity, potentially leaving countries reliant on robust, impartial guidance facing uncertain access to crucial medicines. Their healthcare systems are often delicately balanced, and any perceived capriciousness in the world’s most influential drug regulator rattles those foundations. All of Makary’s initiatives, many lacking formal rulemaking, are now fair game for reversal, adding another layer of uncertainty to a critical federal body that urgently needs a dose of calm.